GRS is under clinical development by Innovative Pharmacology Research and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect GRS’s likelihood of approval (LoA) and phase transition for Stable Angina took place on 19 May 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their GRS Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Small molecule is under development for the treatment of stable angina, hypertension and parenchymal hemorrhage. It is an indolinone-3 derivative. The drug candidate is an anti platelet agent which is administered through oral route in the form of capsule. It acts by targeting soluble guanylate cyclase.
Innovative Pharmacology Research overview
Innovative Pharmacology Research (IPHAR) is a drug development company offering services in the fields of synthesis, analytical chemistry, pharmaceutical development, preclinical and clinical trials, document development, drug registration, IP protection, commercialization and investment attraction, and others. IPHAR is headquartered in Tomsk, Russia.
Quick View GRS LOA Data
|Highest Development Stage|